NASDAQ:VTVT vTv Therapeutics - VTVT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.93 -0.02 (-2.11%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.93▼$0.9850-Day Range$0.66▼$1.0152-Week Range$0.38▼$1.40Volume50,539 shsAverage Volume76,788 shsMarket Capitalization$97.20 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media vTv Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside276.6% Upside$3.50 Price TargetShort InterestBearish4.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 2 Articles This WeekInsider TradingAcquiring Shares$17,047 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.27) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.79 out of 5 starsMedical Sector762nd out of 1,028 stocksPharmaceutical Preparations Industry376th out of 501 stocks 3.5 Analyst's Opinion Consensus RatingvTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, vTv Therapeutics has a forecasted upside of 276.6% from its current price of $0.93.Amount of Analyst CoveragevTv Therapeutics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.14% of the float of vTv Therapeutics has been sold short.Short Interest Ratio / Days to CovervTv Therapeutics has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in vTv Therapeutics has recently decreased by 4.24%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldvTv Therapeutics does not currently pay a dividend.Dividend GrowthvTv Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VTVT. Previous Next 1.9 News and Social Media Coverage News SentimentvTv Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for vTv Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for VTVT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, vTv Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $17,047.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.40% of the stock of vTv Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 8.50% of the stock of vTv Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for vTv Therapeutics are expected to decrease in the coming year, from ($0.27) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of vTv Therapeutics is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of vTv Therapeutics is -3.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About vTv Therapeutics (NASDAQ:VTVT) StockvTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.Read More Receive VTVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VTVT Stock News HeadlinesFebruary 1, 2023 | finance.yahoo.comElizabeth Keiley Selected as Executive Vice President and General Counsel of vTv TherapeuticsJanuary 31, 2023 | reuters.comVTVT.PH - | Stock Price & Latest News | ReutersFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 29, 2023 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Earns Hold Rating from Analysts at StockNews.comJanuary 28, 2023 | americanbankingnews.comvTv Therapeutics (NASDAQ:VTVT) Coverage Initiated by Analysts at StockNews.comJanuary 20, 2023 | finance.yahoo.comPrivate equity firms in vTv Therapeutics Inc. (NASDAQ:VTVT) are its biggest bettors, and their bets paid off as stock gained 21% last weekJanuary 12, 2023 | bizjournals.comvTv Therapeutics names biotechnology industry veteran Steven Tuch as CFOJanuary 9, 2023 | finance.yahoo.comCANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMAFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 5, 2023 | forbes.comVtv TherapeuticsDecember 13, 2022 | finance.yahoo.comvTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial OfficerDecember 3, 2022 | finance.yahoo.comTrade Alert: The Independent Director Of vTv Therapeutics Inc. (NASDAQ:VTVT), John Fry, Has Just Spent US$51k Buying A Few More SharesDecember 1, 2022 | benzinga.comvTv Therapeutics Board Member Makes $50K Stock PurchaseNovember 15, 2022 | finance.yahoo.comThree months after leadership change, vTv Therapeutics reports cash of $15.3 million and net loss of $4.3 million in Q3November 11, 2022 | finanznachrichten.devTv Therapeutics Inc.: vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comvTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comVTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue EstimatesSeptember 23, 2022 | finance.yahoo.comvTv Therapeutics (NASDAQ:VTVT shareholders incur further losses as stock declines 17% this week, taking five-year losses to 84%September 22, 2022 | seekingalpha.comVTVT vTv Therapeutics Inc.August 19, 2022 | finance.yahoo.comThis Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst SaysAugust 19, 2022 | bizjournals.comAfter third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 million net loss in Q2August 18, 2022 | finance.yahoo.comAfter third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 net loss in Q2August 16, 2022 | finance.yahoo.comvTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate UpdateAugust 13, 2022 | finance.yahoo.comWhat You Need To Know About vTv Therapeutics Inc.'s (NASDAQ:VTVT) Investor CompositionAugust 9, 2022 | finance.yahoo.comMonths after celebrating its first exit, CinRx invests $10M in newest portfolio companyJuly 27, 2022 | finance.yahoo.comvTv Therapeutics Announces Paul Sekhri as new President and Chief Executive OfficerJuly 25, 2022 | finance.yahoo.comvTv Therapeutics Shares Jump On Equity InvestmentSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VTVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VTVT Company Calendar Last Earnings11/10/2022Today2/05/2023Next Earnings (Estimated)4/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTVT CUSIPN/A CIK1641489 Webwww.vtvtherapeutics.com Phone(336) 841-0300Fax336-841-0310Employees9Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.50 High Stock Price Forecast$5.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+276.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,990,000.00 Net Margins-364.61% Pretax Margin-1,400.69% Return on EquityN/A Return on Assets-65.89% Debt Debt-to-Equity RatioN/A Current Ratio3.85 Quick Ratio3.85 Sales & Book Value Annual Sales$4.01 million Price / Sales24.24 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-8.45Miscellaneous Outstanding Shares104,580,000Free Float103,113,000Market Cap$97.20 million OptionableNot Optionable Beta-1.06 Key ExecutivesPaul Jai SekhriPresident, Chief Executive Officer & DirectorSteven TuchChief Financial OfficerCarmen ValcarceChief Scientific Officer & Executive VPTrey M. LambertSenior Vice President & General CounselVanessa McDadeChief Administration OfficerKey CompetitorsFortress BiotechNASDAQ:FBIOInflaRxNASDAQ:IFRXReviva PharmaceuticalsNASDAQ:RVPHInozyme PharmaNASDAQ:INZYAraviveNASDAQ:ARAVView All CompetitorsInsiders & InstitutionsJohn A FryBought 20,539 shares on 11/28/2022Total: $17,047.37 ($0.83/share)State Street CorpSold 71,400 shares on 11/15/2022Ownership: 0.129%View All Insider TransactionsView All Institutional Transactions VTVT Stock - Frequently Asked Questions Should I buy or sell vTv Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VTVT shares. View VTVT analyst ratings or view top-rated stocks. What is vTv Therapeutics' stock price forecast for 2023? 2 Wall Street analysts have issued 1 year price objectives for vTv Therapeutics' stock. Their VTVT share price forecasts range from $2.00 to $5.00. On average, they expect the company's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 276.6% from the stock's current price. View analysts price targets for VTVT or view top-rated stocks among Wall Street analysts. How have VTVT shares performed in 2023? vTv Therapeutics' stock was trading at $0.6628 at the beginning of the year. Since then, VTVT stock has increased by 40.2% and is now trading at $0.9294. View the best growth stocks for 2023 here. When is vTv Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023. View our VTVT earnings forecast. How were vTv Therapeutics' earnings last quarter? vTv Therapeutics Inc. (NASDAQ:VTVT) released its quarterly earnings data on Thursday, November, 10th. The biotechnology company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). What other stocks do shareholders of vTv Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA). When did vTv Therapeutics IPO? (VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers. What is vTv Therapeutics' stock symbol? vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT." How do I buy shares of vTv Therapeutics? Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is vTv Therapeutics' stock price today? One share of VTVT stock can currently be purchased for approximately $0.93. How much money does vTv Therapeutics make? vTv Therapeutics (NASDAQ:VTVT) has a market capitalization of $97.19 million and generates $2.02 million in revenue each year. The biotechnology company earns $-12,990,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. How can I contact vTv Therapeutics? vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The official website for the company is www.vtvtherapeutics.com. The biotechnology company can be reached via phone at (336) 841-0300, via email at ir@vtvtherapeutics.com, or via fax at 336-841-0310. This page (NASDAQ:VTVT) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.